α1-Blockers and 5α-Reductase Inhibitors Are the Most Recommended Drugs in Treating Benign Prostatic Hyperplasia: An Evidence-Based Evaluation of Clinical Practice Guidelines

α1-Blockers and 5α-Reductase Inhibitors Are the Most Recommended Drugs in Treating Benign Prostatic Hyperplasia: An Evidence-Based Evaluation of Clinical Practice Guidelines

ObjectiveTo systematically evaluate the quality of clinical practice guidelines (CPG) for medically treating benign prostatic hyperplasia (BPH), and to compare the context of recommendations in order to provide references for clinical application.MethodsWe searched databases of National Guideline Cl...

Full description

Bibliographic Details
Main Authors: Xiao-Feng Xu, Guo-Xiong Liu, Cong Zhu, Xi-Min Qiao, Shao-Fu Yu, Tong Deng, Ying-Hui Jin
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-03-01
Series:Frontiers in Pharmacology
Subjects:
clinical practice guideline
benign prostatic hyperplasia
evidence-based evaluation
AGREE II instrument
medical treatment
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2020.00311/full

Internet

https://www.frontiersin.org/article/10.3389/fphar.2020.00311/full

Similar Items